Intercept Pharma (ICPT) Hit By Laidlaw Upgrade. Has $130 Target; CAREVIEW COMMUNICATIONS (CRVW) Shorts Decreased By 4.16%

CareView Communications, Inc. (OTCMKTS:CRVW) Logo

In a a research report revealed to clients on Monday morning, Laidlaw has upgraded Intercept Pharma (NASDAQ:ICPT) stock to a Buy and has set one year TP at $130. ICPT’s old rating was Hold.

CAREVIEW COMMUNICATIONS INC (OTCMKTS:CRVW) had a decrease of 4.16% in short interest. CRVW’s SI was 334,300 shares in January as released by FINRA. Its down 4.16% from 348,800 shares previously. With 113,900 avg volume, 3 days are for CAREVIEW COMMUNICATIONS INC (OTCMKTS:CRVW)’s short sellers to cover CRVW’s short positions. It closed at $0.02 lastly. It is down 0.00% since January 14, 2018 and is . It has by 0.00% the S&P500.

CareView Communications, Inc. provides products and on-demand application services for the healthcare industry in the United States. The company has market cap of $2.79 million. The firm offers SecureView module to monitor and record bedside activity in the patientÂ’s room; NurseView module to view monitored rooms from the nurseÂ’s station; PhysicianView module to view patients from any personal computer; Virtual Bed Rails and Virtual Chair Rails fall prevention modules; Fall Management Program to separately file, identify, and research the activity of patients; and timed rounding modules to help nursing staff monitor patients. It currently has negative earnings. It also provides Sitter Management Program to monitor patient rooms from nursing station or mobile device; BedView module to monitor the status and availability of facility beds remotely; delivery mechanism for patient education materials; FacilityView module that monitors and records activity in any area that the hospital would desire security cameras to be placed; monitoring system for nursing alerts and reminders; and ulcer management systems.

Another recent and important CareView Communications, Inc. (OTCMKTS:CRVW) news was published by which published an article titled: “Careview Communications Is A Terminal Short – Seeking Alpha” on August 21, 2012.

Analysts await Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report earnings on February, 13. They expect $-2.42 earnings per share, up 45.37% or $2.01 from last year’s $-4.43 per share. After $-2.18 actual earnings per share reported by Intercept Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 11.01% negative EPS growth.

Investors sentiment decreased to 1.25 in 2018 Q3. Its down 0.02, from 1.27 in 2018Q2. It fall, as 17 investors sold Intercept Pharmaceuticals, Inc. shares while 44 reduced holdings. 37 funds opened positions while 39 raised stakes. 18.21 million shares or 7.29% less from 19.65 million shares in 2018Q2 were reported. Elk Creek Ptnrs Ltd has invested 1.6% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Pnc Fin Group Inc has invested 0% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). The Germany-based Dekabank Deutsche Girozentrale has invested 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). 1.20M were reported by Jpmorgan Chase & Com. Highfields Cap Management Limited Partnership, Massachusetts-based fund reported 239,232 shares. Credit Suisse Ag stated it has 103,201 shares or 0.01% of all its holdings. The Switzerland-based Swiss Bancorp has invested 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Hl Services Ltd Liability Co has invested 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Asset Inc invested 0.01% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Chicago Equity Partners Limited, Illinois-based fund reported 1,700 shares. Parametric Portfolio Limited Co holds 0.01% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 58,548 shares. Fisher Asset Management Ltd Com reported 38,475 shares. Prelude Cap Ltd Liability Company has 73 shares. Bancorporation Of America De reported 90,164 shares. Art Advisors Ltd Liability holds 0.04% or 6,145 shares in its portfolio.

Another recent and important Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news was published by which published an article titled: “3 Potential Acquisition Targets for Gilead Sciences, Inc. – The Motley Fool” on November 16, 2016.

The stock increased 0.15% or $0.16 during the last trading session, reaching $109.89. About 261,792 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has risen 72.45% since January 14, 2018 and is uptrending. It has outperformed by 72.45% the S&P500. Some Historical ICPT News: 05/04/2018 – Intercept Pharmaceuticals Announces Pricing of Upsized $250 Million Public Offering and Concurrent Private Placement of Common; 23/03/2018 – Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentations at the International Liver Congress™ 2018; 22/04/2018 – DJ Intercept Pharmaceuticals Inc, Inst Holders, 1Q 2018 (ICPT); 04/04/2018 – INTERCEPT PHARMACEUTICALS REPORTS PROPOSED $120M OFFERING & CON; 08/05/2018 – Intercept Pharmaceuticals Had Cash, Cash Equivalents and Investment Securities Available for Sale of $326.1M at March 31; 02/05/2018 – Intercept Pharma Presenting at UBS Conference May 21; 13/04/2018 – INTERCEPT COMMENTS ON SUBSTUDY FROM POISE PHASE 3 TRIAL; 09/03/2018 INTERCEPT PHARMACEUTICALS INC ICPT.O : WEDBUSH RAISES TARGET PRICE TO $256 FROM $253; 04/04/2018 – ICPT SEES 1Q TOTAL OCALIVA PRESCRIPTIONS FILLED CONSISTENT W/4Q; 31/05/2018 – Intercept Lead in Fatty Liver Disease Threatened by Upstart

Among 9 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Intercept Pharmaceuticals has $217 highest and $95 lowest target. $167.89’s average target is 52.78% above currents $109.89 stock price. Intercept Pharmaceuticals had 9 analyst reports since August 3, 2018 according to SRatingsIntel. Cantor Fitzgerald reinitiated Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rating on Monday, October 1. Cantor Fitzgerald has “Overweight” rating and $170 target. On Monday, August 6 the stock rating was maintained by Wedbush with “Outperform”. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) earned “Buy” rating by Goldman Sachs on Monday, August 6. The stock of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has “Outperform” rating given on Tuesday, October 2 by Raymond James. The rating was downgraded by RBC Capital Markets on Wednesday, August 15 to “Sector Perform”. Oppenheimer upgraded the stock to “Outperform” rating in Monday, November 19 report. The firm has “Hold” rating given on Friday, August 3 by Laidlaw.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.